Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s43440-020-00175-2 http://scihub22266oqcxt.onion/10.1007/s43440-020-00175-2 33108587!7590246!33108587     free     free     free       Pharmacol+Rep 2020 ; 72 (6): 1542-1552 Nephropedia Template TP {{tp|p=33108587|t=2020. Favipiravir use for SARS CoV-2 infection |pdf=|usr=}}{{33108587}} gab.com Text Favipiravir use for SARS CoV-2 infection JO: Pharmacol Rep http://www.kidney.de/pget.php?&tw=1&pmid=33108587 #FOAvip INTRODUCTION: The pandemic of SARS CoV-2 has required urgent medical treatments for numerous patients. As no specific antiviral agents were available, different off-the-shelf alternatives have been explored. OBJECTIVE: Here, we review the rationale behind the use of Favipiravir, and report of the specific studies supporting this treatment being conducted. METHODS: Here we analyze the relevant literature to conclude about the present opportunities offered by this therapeutic agent. RESULTS: This antiviral drug approved influenza in Japan since 2014, has a demonstrated in vitro activity against SARS CoV-2 and is being investigated in several trials for SARS CoV-2. Signals of benefit were shown in a small trial for SARS CoV-2. However, in another small study, there was no advantage. CONCLUSIONS: Further studies, statistically more significant, are urgently needed to understand the best opportunities offered by this treatment. Twit Text FOAVip Favipiravir use for SARS CoV-2 infection ????Pharmacol Rep http://www.kidney.de/pget.php?&tw=1&pmid=33108587 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33108587 #FOAvip English Wikipedia <ref>{{Cite pmid|33108587}}</ref> Favipiravir use for SARS CoV-2 infection #MMPMID33108587 Boretti A Pharmacol Rep 2020[Dec]; 72 (6): 1542-1552 PMID33108587show ga INTRODUCTION: The pandemic of SARS CoV-2 has required urgent medical treatments for numerous patients. As no specific antiviral agents were available, different off-the-shelf alternatives have been explored. OBJECTIVE: Here, we review the rationale behind the use of Favipiravir, and report of the specific studies supporting this treatment being conducted. METHODS: Here we analyze the relevant literature to conclude about the present opportunities offered by this therapeutic agent. RESULTS: This antiviral drug approved influenza in Japan since 2014, has a demonstrated in vitro activity against SARS CoV-2 and is being investigated in several trials for SARS CoV-2. Signals of benefit were shown in a small trial for SARS CoV-2. However, in another small study, there was no advantage. CONCLUSIONS: Further studies, statistically more significant, are urgently needed to understand the best opportunities offered by this treatment. |*COVID-19 Drug Treatment[MESH] |Amides/*therapeutic use[MESH] |Animals[MESH] |Antiviral Agents/*therapeutic use[MESH] |COVID-19/virology[MESH] |Humans[MESH] |Pyrazines/*therapeutic use[MESH] |SARS-CoV-2/drug effects/isolation & purification[MESH]Favipiravir use for SARS CoV-2 infection (epmc).pdf DeepDyve Pubget Overpricing